

BeOne Medicines (ONC US)

First full-year profitability driven by robust BTK sales

BeOne's strong commercial momentum and ongoing cost discipline continue to translate into improving profitability, notwithstanding management's FY26 revenue guidance of US\$6.2–6.4bn, which is modestly below our prior estimate of US\$6.6bn. We continue to see substantial upside for Zanubrutinib (Zanu) to gain market share in the global BTK market driven by new patient prescriptions. BeOne has multiple clinical and regulatory catalysts in 2026 that, if positive, could provide additional support to valuation. We maintain our BUY rating on BeOne with a target price of US\$392.43 (unchanged).

- Strong 4Q25 momentum, led by Zanu.** BeOne reported FY25 total revenue of US\$5.34bn (+40% YoY), modestly above the high end of its US\$5.1–5.3bn guidance range and broadly in line with our prior full-year forecast of US\$5.44bn. Zanu delivered US\$3.93bn in global FY25 sales (+49% YoY). In 4Q25, Zanu sales rose 10% QoQ to US\$1.15bn, continuing to outperform ibrutinib (-4% QoQ) and acalabrutinib (+5% QoQ). Zanu remains the leader in new patient starts in the US across both 1L and R/R CLL (c. 50% share of new prescriptions) and has become the top-selling BTK inhibitor globally on a quarterly revenue basis. As of 4Q25, sales of Zanu represented approximately 36% of the global BTK inhibitor class. We expect continued share gains versus legacy BTK inhibitors and alternative regimens, and forecast Zanu sales of US\$4.67bn in FY26E (+19% YoY).
- First full-year profitability achieved in FY25.** Following its first-ever quarterly GAAP profit in 1Q25, BeOne sustained its profitability trajectory through FY25, delivering its first full-year GAAP net income of US\$287mn, underpinned by robust top-line growth and improved operating leverage. Operating efficiency also strengthened, with the SG&A-to-sales ratio declining to 39.4% (vs. 48.5% in FY24) and the R&D-to-sales ratio moderating to 40.6% (vs. 51.7% in FY24). Management guided FY26 revenue of US\$6.2–6.4bn, modestly below our prior estimate of US\$6.6bn. Nevertheless, we believe BeOne remains on track for solid earnings growth, driven by Zanu's expanding market share.
- Multiple near-term catalysts.** We anticipate multiple near-term catalysts that, if positive, will drive BeOne's valuation upside. On the regulatory front, the NDA for sonroticla (BCL-2) in R/R MCL is under FDA review with a PDUFA date in 1H26; approval would unlock global commercialization following its prior approval in China for R/R MCL and R/R CLL. In the breast cancer franchise, we expect the Company to initiate a Ph3 trial for its CDK4i in 1L HR+ breast cancer in 1H26, alongside the presentation of Ph1 data (1L and later-line) at a medical conference. Additionally, we look for Ph1 data releases for B7-H4 ADC and GPC3 x 4-1BB bsAb in 1H26, with the former to enter Ph3 within 12 months and the latter to start a potential pivotal Ph2 in 2H26. Finally, 2H26 catalysts include a potential US NDA submission for the BTK CDAC (based on Ph2 data in R/R CLL) and initial data disclosures for the PRMT5i and CEA ADC programs.
- Maintain BUY.** While we have slightly lowered 2026 revenue forecast to align with management's guidance, this impact is offset by the strengthened net cash position following the sale of tarlatamab royalties. We maintain TP unchanged at US\$392.47 (WACC: 9.64%, terminal growth rate: 3.5%).

Earnings Summary

(YE 31 Dec)	FY24A	FY25A	FY26E	FY27E	FY28E
Revenue (US\$ mn)	3,810	5,343	6,320	7,249	8,135
Net profit (US\$ mn)	(644.8)	286.9	684.5	1,246.0	1,696.4
EPS (Reported) (US\$)	(6.12)	2.63	5.78	10.51	14.31
P/S (x)	9.9	7.0	5.9	5.2	4.6
P/E (x)	ns	120.5	54.9	30.1	22.1

Source: Company data, Bloomberg, CMBIGM estimates

BUY (Maintain)

Target Price	US\$392.43
(Previous TP)	US\$392.43)
Up/Downside	23.8%
Current Price	US\$316.99

China Healthcare

Jill WU, CFA

(852) 3900 0842
jillwu@cmbi.com.hk

Andy WANG

(852) 3657 6288
andywang@cmbi.com.hk

Stock Data

Mkt Cap (US\$ mn)	37,567.7
Avg 3 mths t/o (US\$ mn)	85.8
52w High/Low (US\$)	377.47/206.32
Total Issued Shares (mn)	118.5

Source: FactSet

Shareholding Structure

Amgen	16.9%
Baker Bros	7.9%

Source: Bloomberg

Share Performance

	Absolute	Relative
1-mth	-5.7%	-1.8%
3-mth	-6.9%	-5.6%
6-mth	5.6%	-0.3%


Source: FactSet

12-mth Price Performance




Source: FactSet

Figure 1: Quarterly product sales of BeOne




Source: Company data, CMBIGM

Figure 2: Zanubrutinib quarterly sales



Source: Company data, CMBIGM

Figure 3: Tislelizumab quarterly sales



Source: Company data, CMBIGM

Figure 4: Risk-adjusted DCF valuation

DCF valuation (US\$ mn)	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E	2035E
EBIT	725	1,419	1,930	2,264	3,042	3,713	4,291	4,601	4,723	4,789
Tax rate	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%
EBIT*(1-tax rate)	617	1,206	1,640	1,924	2,585	3,156	3,647	3,911	4,014	4,071
+ D&A	146	151	151	150	146	143	139	136	133	131
- Change in working capital	-35	-149	-142	10	-189	-136	-117	-40	-7	12
- Capex	-200	-200	-150	-150	-100	-100	-100	-100	-100	-100
FCFF	527	1,008	1,499	1,934	2,443	3,063	3,570	3,907	4,041	4,113
Terminal value										69,339
PV of enterprise (US\$ mn)	41,874									
Net debt (US\$ mn)	-4,634									
Equity value (US\$ mn)	46,509									
No. of ADS (mn)	119									
DCF per ADS (US\$)	392.43									
Terminal growth rate	3.5%									
WACC	9.64%									
Cost of equity	13.0%									
Cost of debt	4.0%									
Equity beta	1.00									
Risk-free rate	3.0%									
Market risk premium	10.0%									
Target debt to asset ratio	35.0%									
Effective corporate tax rate	15.0%									

Source: CMBIGM estimates

Figure 5: Sensitivity analysis (US\$)

Terminal growth rate	WACC				
	8.64%	9.14%	9.64%	10.14%	10.64%
4.5%	549.03	488.84	440.47	400.77	367.62
4.0%	506.18	455.72	414.32	379.76	350.48
3.5%	471.66	428.48	392.43	361.91	335.75
3.0%	443.26	405.67	373.84	346.56	322.94
2.5%	419.49	386.29	357.85	333.22	311.71

Figure 6: CMBIGM estimates: New vs Old

US\$ mn	New			Old			Diff (%)		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Revenue	6,320	7,249	8,135	6,644	7,778	8,707	-5%	-7%	-7%
Gross Profit	5,539	6,367	7,161	5,760	6,759	7,584	-4%	-6%	-6%
Operating Profit	725	1,419	1,930	1,043	1,548	2,186	-30%	-8%	-12%
Net profit	684	1,246	1,696	919	1,346	1,904	-26%	-7%	-11%
EPS (US\$)	5.78	10.51	14.31	8.30	12.16	17.21	-30%	-14%	-17%
Gross Margin	87.64%	87.83%	88.03%	86.70%	86.90%	87.10%	+0.94 ppt	+0.93 ppt	+0.93 ppt
Operating Margin	11.48%	19.57%	23.72%	15.70%	19.90%	25.10%	-4.22 ppt	-0.33 ppt	-1.38 ppt
Net Margin	10.83%	17.19%	20.85%	13.83%	17.30%	21.87%	-3.00 ppt	-0.11 ppt	-1.02 ppt

Source: Company data, CMBIGM estimates

Figure 7: CMBIGM estimate vs consensus

US\$ mn	CMBIGM			Consensus			Diff (%)		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Revenue	6,320	7,249	8,135	6,382	7,294	8,073	-1%	-1%	1%
Gross Profit	5,539	6,367	7,161	5,518	6,338	7,013	0%	0%	2%
Operating Profit	725	1,419	1,930	847	1,307	1,619	-14%	9%	19%
Net profit	684	1,246	1,696	713	1,187	1,542	-4%	5%	10%
EPS (US\$)	5.78	10.51	14.31	6.90	12.20	13.12	-16%	-14%	9%
Gross Margin	87.64%	87.83%	88.03%	86.47%	86.89%	86.87%	+1.17 ppt	+0.94 ppt	+1.16 ppt
Operating Margin	11.48%	19.57%	23.72%	13.27%	17.92%	20.05%	-1.79 ppt	+1.66 ppt	+3.67 ppt
Net Margin	10.83%	17.19%	20.85%	11.17%	16.27%	19.10%	-0.34 ppt	+0.92 ppt	+1.75 ppt

Source: Company data, Bloomberg, CMBIGM estimates

Financial Summary

INCOME STATEMENT	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec (US\$ mn)						
Revenue	2,459	3,810	5,343	6,320	7,249	8,135
Cost of goods sold	(380)	(594)	(669)	(781)	(882)	(974)
Gross profit	2,079	3,216	4,674	5,539	6,367	7,161
Operating expenses	(3,287)	(3,784)	(4,227)	(4,813)	(4,948)	(5,232)
SG&A expense	(1,505)	(1,831)	(2,081)	(2,438)	(2,725)	(2,817)
R&D expense	(1,779)	(1,953)	(2,146)	(2,375)	(2,223)	(2,415)
Others	(4)	0	0	0	0	0
Other income	382	35	(30)	80	47	66
Pre-tax profit	(826)	(533)	417	805	1,466	1,996
Income tax	(56)	(112)	(130)	(121)	(220)	(299)
Minority interest	0	0	0	0	0	0
Net profit	(882)	(645)	287	684	1,246	1,696
Adjusted net profit	(882)	(645)	287	684	1,246	1,696
BALANCE SHEET						
YE 31 Dec (US\$ mn)						
Current assets	4,203	3,992	6,234	7,202	8,763	11,015
Cash & equivalents	3,172	2,627	4,548	5,454	6,812	8,878
Account receivables	358	676	865	902	1,034	1,161
Inventories	416	495	608	634	704	764
Financial assets at FVTPL	3	0	0	0	0	0
Other current assets	255	193	213	213	213	213
Non-current assets	1,602	1,929	1,955	2,009	2,058	2,058
PP&E	1,324	1,578	1,642	1,695	1,745	1,744
Deferred income tax	0	0	0	0	0	0
Intangibles	57	51	63	63	63	63
Other non-current assets	221	300	251	251	251	251
Total assets	5,805	5,921	8,189	9,211	10,821	13,073
Current liabilities	1,810	2,215	1,829	1,856	1,909	1,954
Short-term borrowings	688	852	57	57	57	57
Account payables	315	405	479	506	559	604
Tax payable	23	26	42	42	42	42
Other current liabilities	784	932	1,251	1,251	1,251	1,251
Non-current liabilities	458	374	1,999	1,799	1,599	1,599
Long-term borrowings	198	166	962	762	562	562
Deferred income	0	0	0	0	0	0
Other non-current liabilities	260	207	186	186	186	186
Total liabilities	2,268	2,589	3,827	3,654	3,507	3,552
Share capital	11,599	12,088	12,759	13,270	13,781	14,292
Retained earnings	(7,962)	(8,607)	(8,320)	(7,635)	(6,389)	(4,693)
Other reserves	(99)	(149)	(78)	(78)	(78)	(78)
Total shareholders equity	3,537	3,332	4,361	5,556	7,313	9,521
Minority interest	0	0	0	0	0	0
Total equity and liabilities	5,805	5,921	8,188	9,211	10,821	13,073

CASH FLOW	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec (US\$ mn)						
Operating						
Profit before taxation	(826)	(533)	417	805	1,466	1,996
Depreciation & amortization	88	172	142	146	151	151
Tax paid	(56)	(112)	(130)	(121)	(220)	(299)
Others	(363)	332	699	475	362	369
Net cash from operations	(1,157)	(141)	1,128	1,306	1,758	2,216
Investing						
Capital expenditure	(562)	(493)	(186)	(200)	(200)	(150)
Acquisition of subsidiaries/ investments	(17)	(22)	(12)	0	0	0
Net proceeds from disposal of short-term investments	673	3	3	0	0	0
Others	(34)	(36)	(82)	0	0	0
Net cash from investing	60	(548)	(276)	(200)	(200)	(150)
Financing						
Net borrowings	684	877	1,084	0	0	0
Proceeds from share issues	0	0	907	0	0	0
Others	(268)	(684)	(932)	(200)	(200)	0
Net cash from financing	416	193	1,059	(200)	(200)	0
Net change in cash						
Cash at the beginning of the year	3,875	3,186	2,639	4,548	5,454	6,812
Exchange difference	(8)	(52)	60	0	0	0
Cash at the end of the year	3,186	2,639	4,610	5,454	6,812	8,878
GROWTH	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec						
Revenue	73.7%	55.0%	40.2%	18.3%	14.7%	12.2%
Gross profit	84.1%	54.7%	45.3%	18.5%	15.0%	12.5%
Net profit	na	na	na	138.5%	82.0%	36.1%
Adj. net profit	na	na	na	138.5%	82.0%	36.1%
PROFITABILITY	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec						
Gross profit margin	84.5%	84.4%	87.5%	87.6%	87.8%	88.0%
Adj. net profit margin	(35.9%)	(16.9%)	5.4%	10.8%	17.2%	20.9%
Return on equity (ROE)	(22.3%)	(18.8%)	7.5%	13.8%	19.4%	20.2%
GEARING/LIQUIDITY/ACTIVITIES	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec						
Net debt to equity (x)	(0.7)	(0.5)	(0.8)	(0.8)	(0.8)	(0.9)
Current ratio (x)	2.3	1.8	3.4	3.9	4.6	5.6
Receivable turnover days	39.4	49.5	52.6	52.6	52.6	52.6
Inventory turnover days	335.5	279.9	301.2	296.2	291.2	286.2
Payable turnover days	293.0	221.2	241.3	236.3	231.3	226.3
VALUATION	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec						
P/E	ns	ns	120.5	54.9	30.1	22.1
P/E (diluted)	ns	ns	125.3	54.9	30.1	22.1
P/B	121.6	130.2	103.1	87.9	66.8	51.3

Source: Company data, CMBIGM estimates. Note: The calculation of net cash includes financial assets.

Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings

BUY : Stock with potential return of over 15% over next 12 months
HOLD : Stock with potential return of +15% to -10% over next 12 months
SELL : Stock with potential loss of over 10% over next 12 months
NOT RATED : Stock is not rated by CMBIGM

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.